BioCryst Pharmaceuticals and Idera Pharmaceuticals failed to merge.

BioCryst Pharmaceuticals, a company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases, and Idera Pharmaceuticals, a clinical-stage biopharmaceutical company committed to transforming the care of people living with rare pulmonary and rheumatic diseases, failed to merge. “We respect and understand the views of our stockholders and are moving forward fully-focused on executing our business plan as a standalone company. The BioCryst Board and management team remain confident in BCX-7353 and our ability to execute on our plan and advance our programs,” Jon P. Stonehouse, BioCryst President and CEO.